

# Masayuki Nakagawa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5732837/publications.pdf>

Version: 2024-02-01

57  
papers

2,441  
citations

186265

28  
h-index

197818

49  
g-index

59  
all docs

59  
docs citations

59  
times ranked

3793  
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting of the glutamine transporter SLC1A5 induces cellular senescence in clear cell renal cell carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2022, 611, 99-106.	2.1	4
2	Significance of preoperative screening of deep vein thrombosis and its indications for patients undergoing urological surgery. <i>Investigative and Clinical Urology</i> , 2021, 62, 166.	2.0	0
3	Surveillance of urachal abscess in the Kyushu-Okinawa area of Japan. <i>International Journal of Urology</i> , 2021, 28, 1008-1011.	1.0	2
4	EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer. <i>BMC Cancer</i> , 2021, 21, 48.	2.6	19
5	Oncological outcome of neoadjuvant low-dose estramustine plus LHRH agonist/antagonist followed by extended radical prostatectomy for Japanese patients with high-risk localized prostate cancer: a prospective single-arm study. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 66-72.	1.3	5
6	Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma. <i>PLoS ONE</i> , 2020, 15, e0236119.	2.5	20
7	Potential new therapy of Rapalink1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma. <i>Cancer Science</i> , 2020, 111, 1607-1618.	3.9	38
8	Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation. <i>Molecular Oncology</i> , 2020, 14, 2190-2202.	4.6	17
9	Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistant. <i>PLoS ONE</i> , 2020, 15, e0232545.	2.5	19
10	Clinical Practice Guidelines for Bladder Cancer 2019 update by the Japanese Urological Association: Summary of the revision. <i>International Journal of Urology</i> , 2020, 27, 702-709.	1.0	65
11	Successful Kidney Transplantation Alone With Severe Left Ventricular Systolic Dysfunction of Ejection Fraction 14%: A Case Report. <i>Transplantation Proceedings</i> , 2020, 52, 1919-1923.	0.6	1
12	Clinical Practice Guidelines for Bladder Cancer 2019 edition by the Japanese Urological Association: Revision working position paper. <i>International Journal of Urology</i> , 2020, 27, 362-368.	1.0	25
13	A new risk stratification model for intravesical recurrence, disease progression, and cancer-specific death in patients with non-muscle invasive bladder cancer: the J-NICE risk tables. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1364-1376.	2.2	14
14	The long-term prognosis of nephropathy in operated reflux. <i>Journal of Pediatric Urology</i> , 2019, 15, 605.e1-605.e8.	1.1	6
15	Kidney transplantation with concomitant simple nephrectomy by thoracoabdominal approach for patients with huge autosomal dominant polycystic kidney disease (ADPKD): A case report. <i>Urology Case Reports</i> , 2019, 26, 100973.	0.3	0
16	Tumor-suppressive microRNA-223 targets WDR62 directly in bladder cancer. <i>International Journal of Oncology</i> , 2019, 54, 2222-2236.	3.3	16
17	Anatomical Variations of the Left Renal Vein During Laparoscopic Donor Nephrectomy. <i>Transplantation Proceedings</i> , 2019, 51, 1311-1313.	0.6	6
18	Potential tumor-suppressive role of microRNA-99a-3p in sunitinib-resistant renal cell carcinoma cells through the regulation of RRM2. <i>International Journal of Oncology</i> , 2019, 54, 1759-1770.	3.3	24

#	ARTICLE	IF	CITATIONS
19	Immunoabsorption plasmapheresis treatment for the recurrent exacerbation of neuromyelitis optica spectrum disorder with a fluctuating anti-aquaporin-4 antibody level. <i>Journal of Artificial Organs</i> , 2018, 21, 378-382.	0.9	8
20	HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer. <i>International Journal of Oncology</i> , 2018, 53, 725-736.	3.3	22
21	Long-term desensitization for ABO-incompatible living related kidney transplantation recipients with high refractory and rebound anti-blood type antibody: case report. <i>BMC Nephrology</i> , 2018, 19, 254.	1.8	3
22	Oral Propranolol in a Child With Infantile Hemangioma of the Urethra. <i>Urology</i> , 2018, 122, 165-168.	1.0	3
23	Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma. <i>Oncotarget</i> , 2018, 9, 23003-23017.	1.8	28
24	Is It Safe to Use the Same Scissors After Accidental Tumor Incision During Partial Nephrectomy? Results of <i>In Vitro</i> and <i>In Vivo</i> Experiments. <i>Journal of Endourology</i> , 2017, 31, 391-395.	2.1	4
25	Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer. <i>British Journal of Cancer</i> , 2017, 116, 1077-1087.	6.4	48
26	PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2 $\alpha$ -Targeting Therapy for Renal Cell Carcinoma. <i>Cancer Research</i> , 2017, 77, 6321-6329.	0.9	60
27	Downregulation of microRNA-1274a induces cell apoptosis through regulation of BMPR1B in clear cell renal cell carcinoma. <i>Oncology Reports</i> , 2017, 39, 173-181.	2.6	18
28	microRNA-210-3p depletion by CRISPR/Cas9 promoted tumorigenesis through revival of TWIST1 in renal cell carcinoma. <i>Oncotarget</i> , 2017, 8, 20881-20894.	1.8	57
29	Regulation of <i>UHRF1</i> by dual-strand tumor-suppressor <i>microRNA-145</i> ( <i>miR-145-5p</i> and <i>miR-145-3p</i> ): inhibition of bladder cancer cell aggressiveness. <i>Oncotarget</i> , 2016, 7, 28460-28487.	1.8	93
30	The role of microRNAs in bladder cancer. <i>Investigative and Clinical Urology</i> , 2016, 57, S60.	2.0	75
31	Tumor-suppressive <i>microRNA-223</i> inhibits cancer cell migration and invasion by targeting <i>ITGA3</i> / <i>ITGB1</i> signaling in prostate cancer. <i>Cancer Science</i> , 2016, 107, 84-94.	3.9	122
32	Dual tumor-suppressors <i>miR-139-5p</i> and <i>miR-139-3p</i> targeting <i>matrix metalloproteinase 11</i> in bladder cancer. <i>Cancer Science</i> , 2016, 107, 1233-1242.	3.9	115
33	Acute Kidney Injury and Rhabdomyolysis After Protobothrops flavoviridis Bite: A Retrospective Survey of 86 Patients in a Tertiary Care Center. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 94, 474-479.	1.4	14
34	Tumor-suppressive microRNA-29 family inhibits cancer cell migration and invasion directly targeting LOXL2 in lung squamous cell carcinoma. <i>International Journal of Oncology</i> , 2016, 48, 450-460.	3.3	55
35	Tumor-suppressive microRNAs ( <i>miR-26a/b</i> , <i>miR-29a/b/c</i> and <i>miR-218</i> ) concertedly suppressed metastasis-promoting LOXL2 in head and neck squamous cell carcinoma. <i>Journal of Human Genetics</i> , 2016, 61, 109-118.	2.3	59
36	Dual regulation of receptor tyrosine kinase genes EGFR and c-Met by the tumor-suppressive microRNA-23b/27b cluster in bladder cancer. <i>International Journal of Oncology</i> , 2015, 46, 487-496.	3.3	82

#	ARTICLE	IF	CITATIONS
37	<i>MicroRNA-205</i> inhibits cancer cell migration and invasion via modulation of centromere protein F regulating pathways in prostate cancer. <i>International Journal of Urology</i> , 2015, 22, 867-877.	1.0	29
38	Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR oncogenic signaling in lung squamous cell carcinoma. <i>International Journal of Oncology</i> , 2015, 46, 1039-1050.	3.3	40
39	MicroRNA-26a/b directly regulate La-related protein 1 and inhibit cancer cell invasion in prostate cancer. <i>International Journal of Oncology</i> , 2015, 47, 710-718.	3.3	62
40	The tumor-suppressive microRNA-1/133a cluster targets PDE7A and inhibits cancer cell migration and invasion in endometrial cancer. <i>International Journal of Oncology</i> , 2015, 47, 325-334.	3.3	24
41	Tumour-suppressive microRNA-29s directly regulate LOXL2 expression and inhibit cancer cell migration and invasion in renal cell carcinoma. <i>FEBS Letters</i> , 2015, 589, 2136-2145.	2.8	66
42	Mucinous adenocarcinoma emerging in sigmoid colon neovagina 40 years after its creation: a case report. <i>World Journal of Surgical Oncology</i> , 2015, 13, 213.	1.9	24
43	MicroRNA expression signature of castration-resistant prostate cancer: the microRNA-221/222 cluster functions as a tumour suppressor and disease progression marker. <i>British Journal of Cancer</i> , 2015, 113, 1055-1065.	6.4	107
44	Downregulation of the microRNA-1/133a cluster enhances cancer cell migration and invasion in lung-squamous cell carcinoma via regulation of Coronin1C. <i>Journal of Human Genetics</i> , 2015, 60, 53-61.	2.3	61
45	Genome-wide association study identified SNP on 15q24 associated with bladder cancer risk in Japanese population. <i>Human Molecular Genetics</i> , 2015, 24, 1177-1184.	2.9	38
46	Expression of the Tumor SuppressivemiRNA-23b/27bCluster is a Good Prognostic Marker in Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 192, 1822-1830.	0.4	52
47	Tumour-suppressive microRNA-224 inhibits cancer cell migration and invasion via targeting oncogenic TPD52 in prostate cancer. <i>FEBS Letters</i> , 2014, 588, 1973-1982.	2.8	76
48	Occurrence of infection following prostate biopsy procedures in Japan. <i>Journal of Infection and Chemotherapy</i> , 2014, 20, 232-237.	1.7	28
49	The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. <i>Journal of Human Genetics</i> , 2014, 59, 78-87.	2.3	112
50	Tumour-suppressivemicroRNA-24-1inhibits cancer cell proliferation through targetingFOXM1in bladder cancer. <i>FEBS Letters</i> , 2014, 588, 3170-3179.	2.8	52
51	Tumor-suppressive microRNA-29s inhibit cancer cell migration and invasion via targeting LAMC1 in prostate cancer. <i>International Journal of Oncology</i> , 2014, 45, 401-410.	3.3	93
52	The MicroRNA Expression Signature of Bladder Cancer by Deep Sequencing: The Functional Significance of the miR-195/497 Cluster. <i>PLoS ONE</i> , 2014, 9, e84311.	2.5	142
53	The microRNA-23b/27b/24-1 cluster is a disease progression marker and tumor suppressor in prostate cancer. <i>Oncotarget</i> , 2014, 5, 7748-7759.	1.8	115
54	Expression of ABCB6 is related to resistance to 5-FU, SN-38 and vincristine. <i>Anticancer Research</i> , 2014, 34, 4767-73.	1.1	14

#	ARTICLE	IF	CITATIONS
55	Clinicopathological features of renal cell carcinoma complicated by ACDK in chronic hemodialysis patients.. Nihon Toseki Igakkai Zasshi, 2002, 35, 1495-1501.	0.1	0
56	Endoscopic treatment of a long fibroepithelial ureteral polyp. International Journal of Urology, 2001, 8, 467-469.	1.0	27
57	Elevated expression of vacuolar proton pump genes and cellular ph in cisplatin resistance. International Journal of Cancer, 2001, 93, 869-874.	5.1	128